Douglas Cerretti - Cellcyte Genetics Insider

Cellcyte Genetics -- USA Stock  

USD 0.0001  0.00  0.00%

President, Chief Science Officer and Director of Bus. Devel.

Dr. Douglas P. Cerretti, Ph.D., is President of CellCyte Genetics Corporationrationration. He is a biopharmaceutical research scientist with experience in drug development in inflammation and cancer. From 1984 to 2002, he served with Immunex, and, after Immunex acquisition in 2002, with Amgen in positions ranging from Staff Scientist through Scientific Director. Dr. Cerretti retired from Amgen in 2007. He is the author or coauthor of more than 100 scientific publications and has over 40 issued US Patents to his name
Age: 61  President Since 2010  Ph.D    
Cerretti has worked with Company since October 2009, initially as Chief Science Officer and Director of Business Development, where he helped formulate scientific and business strategies. He has also worked as a senior scientific consultant through DPC BioPharma Consulting of Seattle, Washington since 2008, formulating a business plan and scientific strategies for a potential stem cell product. From 2002 through 2007, Dr. Cerretti served as Scientific Director and Senior Research Scientist, Department of Cancer Biology for Amgen Corporationrationrationration. From 1984 through 2002, he served as a Senior Research Scientist for Immunex Corporationrationrationration within their departments of Vascular and Molecular Biology.

Management Efficiency

The company has return on total asset (ROA) of (415.29) % which means that it has lost $415.29 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (22.9) % meaning that it created substantial loss on money invested by shareholders.

Similar Executives

Entity Summary

CellCyte Genetics Corporationration, a development stage biotechnology company, engages in the research and development of medical devices for cell expansion and maintenance in the United States. Cellcyte Genetics [CCYG] is traded as part of a regulated electronic over-the-counter service offered by the NASD.

Did you try this?

Run Chance of Distress Now

Chance of Distress

Get analysis of equity chance of financial distress in the next 2 years
Hide  View All  NextLaunch Chance of Distress
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Cellcyte Genetics to your portfolio

Other Leaders

Cellcyte Genetics Management Team
John Fluke, Chairman
Randy Lieber, Director, CPA
Douglas Cerretti, President, Ph.D

Stock Performance

Cellcyte Genetics Performance Indicators